tiprankstipranks
Trending News
More News >

Argenica Therapeutics Advances Phase 2 Trial for Stroke Treatment

Story Highlights
Argenica Therapeutics Advances Phase 2 Trial for Stroke Treatment

Don’t Miss TipRanks’ Half-Year Sale

An announcement from Argenica Therapeutics Ltd ( (AU:AGN) ) is now available.

Argenica Therapeutics has made significant progress in its Phase 2 clinical trial of ARG-007 for acute ischaemic stroke, with the final patient dosed and topline data expected in Q3 2025. The trial, which involves 92 patients, aims to assess the safety and efficacy of ARG-007, with results potentially impacting the company’s market positioning in stroke treatment. Additionally, preclinical studies suggest ARG-007 could prevent axonal injury and neuroinflammation in traumatic brain injury, further supporting its potential utility in neurological treatments.

More about Argenica Therapeutics Ltd

Argenica Therapeutics Limited is a biotechnology company focused on developing novel therapeutics aimed at reducing brain tissue death following strokes and other brain injuries. The company’s primary product, ARG-007, is currently undergoing a Phase 2 clinical trial in acute ischaemic stroke patients across Australian hospitals. Argenica is also exploring the potential applications of ARG-007 in other neurological conditions, supported by over $4 million in non-dilutive funding from various government and philanthropic sources.

YTD Price Performance: 7.94%

Average Trading Volume: 133,080

Technical Sentiment Signal: Hold

For a thorough assessment of AGN stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1